Peter Lawson Analyst Performance

US Biotech Equity Analyst - Managing Director at Barclays

Peter Lawson is a stock analyst at Barclays focused in the medical sector, covering 35 publicly traded companies. Over the past year, Peter Lawson has issued 23 stock ratings, including buy, hold, and sell recommendations. While full access to Peter Lawson's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Peter Lawson's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Ranking: Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat
Average Return: 00.00% 12-Month ROI
Success Rate: 00.00% Profitable Ratings
Total Ratings: 78 Last 10 Years
Buy Recommendations: 67.95% 53 Buy Ratings
Companies Covered: 35 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	0.0%	0 ratings
Buy	67.9%	53 ratings
Hold	29.5%	23 ratings
Sell	2.6%	2 ratings

Out of 78 total stock ratings issued by Peter Lawson at Barclays, the majority (67.9%) have been Buy recommendations, followed by 29.5% Hold and 2.6% Sell.

Best & Worst Calls

Best Call
0000.0%
REPL
May 2020
Subscribe to MarketBeat All Access to get analyst recommendation ROI.
Worst Call
000.0%
CLVS
Jul 2015
Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	94.3% of companies on NASDAQ	33 companies
NYSE	2.9% of companies on NYSE	1 company
NYSEAMERICAN	2.9% of companies on NYSEAMERICAN	1 company

Peter Lawson, an analyst at Barclays, currently covers 35 companies listed on NASDAQ, NYSE and NYSEAMERICAN, with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 33 companies	94.3%
	Miscellaneous 2 companies	5.7%

Peter Lawson of Barclays specializes in stock coverage within the Medical sector, with additional focus on companies.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 20 companies	57.1%
PHARMACEUTICAL PREPARATIONS 4 companies	11.4%
MED - DRUGS 3 companies	8.6%
MED PRODUCTS 2 companies	5.7%
Miscellaneous 2 companies	5.7%
MEDICAL INFO SYS 1 company	2.9%
DIAGNOSTIC SUBSTANCES 1 company	2.9%
ANALYTICAL INSTRUMENTS 1 company	2.9%
BIOTECHNOLOGY 1 company	2.9%

Timeframe

Start Date

End Date

Rating

12-Month ROIAll ROI

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating
ONC BeOne Medicines	9/18/2025	Initiated Coverage	$332.20	$385.00	Overweight
IDYA IDEAYA Biosciences	9/4/2025	Initiated Coverage	$25.76	$40.00	Overweight
IDYA IDEAYA Biosciences	9/4/2025	Initiated Coverage	$25.83	$40.00	Overweight
SDGR Schrodinger	8/14/2025	Initiated Coverage	$19.84	$25.00	Overweight
SDGR Schrodinger	8/14/2025	Initiated Coverage	$19.45	$25.00	Overweight
REPL Replimune Group	7/23/2025	Downgrade	$2.81	$3.00	Equal Weight
EXEL Exelixis	7/10/2025	Boost Price Target	$44.75	$40.00	Equal Weight
MGNX MacroGenics	5/14/2025	Reiterated Rating	$1.54	$3.00	Overweight
FATE Fate Therapeutics	5/14/2025	Lower Price Target	$0.98	$2.00	Overweight
ADAP Adaptimmune Therapeutics	5/14/2025	Lower Price Target	$0.28	$0.46	Underweight
KPTI Karyopharm Therapeutics	5/13/2025	Boost Price Target	$5.30	$10.00	Overweight
IOVA Iovance Biotherapeutics	5/12/2025	Lower Price Target	$1.81	$4.00	Overweight
XNCR Xencor	5/8/2025	Lower Price Target	$8.98	$6.00	Underweight
KURA Kura Oncology	5/2/2025	Lower Price Target	$6.34	$11.00	Overweight
ARVN Arvinas	5/2/2025	Lower Price Target	$7.08	$16.00	Overweight
BCYC Bicycle Therapeutics	5/1/2025	Lower Price Target	$9.08	$15.00	Overweight
SWTX SpringWorks Therapeutics	4/28/2025	Reiterated Rating	$46.18	$47.00	Equal Weight
RCUS Arcus Biosciences	4/23/2025	Lower Price Target	$8.11	$14.00	Overweight
IOVA Iovance Biotherapeutics	4/14/2025	Lower Price Target	$3.43	$5.00	Overweight
BMEA Biomea Fusion	4/2/2025	Lower Price Target	$2.05	$3.00	Equal Weight
TCRX TScan Therapeutics	3/7/2025	Lower Price Target	$2.08	$3.00	Overweight
EXEL Exelixis	2/13/2025	Boost Price Target	$33.98	$29.00	Equal Weight
ARVN Arvinas	2/3/2025	Lower Price Target	$17.61	$32.00	Overweight

Stock Forecasts and Research Tools

Today's Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.